Hugues Wallemacq

Noshaq Representative

Hugues holds a Doctorate in Veterinary Medicine (DVM) and a PhD in Immunology. He brings extensive operational and executive experience across biotech, biopharma and medtech, gained through roles at GSK, Unisensor and EXO Biologics. He is currently CEO of Man & Science, where he leads the development of innovative therapeutic devices. As Noshaq’s representative on the boards of several portfolio companies, including Amyl Therapeutics, Livedrop, SignaturBio and Convert Pharmaceuticals, he contributes to strategic oversight, clinical development and corporate growth.